


Press release  
 July 5, 2024

## Pediatric cancer: the origin of the medulloblastoma detected, renewed hope

For the first time, the cellular identity and the developmental time at the origin of medulloblastoma, the most common pediatric brain tumor, have been identified. The genealogy and the precise characteristics of the cells involved in this phenomenon during human embryonic development have been elucidated thanks to the work of Dr. Olivier Saulnier, which was started at The Hospital for Sick Children in Toronto (Canada) and completed at Institut Curie<sup>1</sup>. Published in *Cell* on July 5, 2024, this work paves the way for the development of new targeted therapies against these pediatric cancers.

Medulloblastoma is the most common brain cancer in children. It develops in the cerebellum and belongs to a very heterogeneous group of tumors. Among these tumors, Group 3 medulloblastoma is poorly characterized and is among the most aggressive. Unlike adult cancers that result from aging and exposure to mutagens, pediatric cancers emerge from dysregulation of the developmental programs that govern normal cell fate decisions.

Medulloblastoma develops from a fetal region in the cerebellum, however, until now the precise cell at the origin of these tumors was not known. Today, the Genomics and Development of Childhood Cancer Team of Dr. Olivier Saulnier at Institut Curie (Cancer, Heterogeneity, Instability and Plasticity unit - CHIP U830 (Inserm, Institut Curie)), in collaboration with his Canadian colleagues, unveil **the mechanisms at the origin of group 3 medulloblastoma, in particular the cellular and molecular mapping of this cell type during early human embryogenesis.**



### The cell of origin unmasked

By tracking stem cells and their progeny in human embryonic tissues, the researchers revealed the detailed characteristics of the cell at the origin of group 3 medulloblastoma, so-called *cell of origin*. The precise identity of this cell has been determined via the use of bioinformatics making it possible to study genomic data at the single cell level. By comparing the tumor programs with the human embryonic developmental programs, the scientists managed to identify that the cell of origin expresses **an embryonic marker named Protogenin (PRTG)**. During human development, this marker

is expressed only during the first weeks of pregnancy and is therefore not expressed during adult life. This fetal "fingerprint" is very important because thanks to it, it is possible to imagine new therapies targeting the cells at the origin of these tumors.

This is what the researchers have demonstrated: **targeting PRTG-expressing cells reduce tumor growth and increase survival *in vivo* in pre-clinical models of medulloblastoma.**

*"By identifying this onco-fetal marker in very young children, we could imagine preventing the disease even before it develops and therefore blocking the process of tumorigenesis. This work will have considerable implications in the fight against various pediatric cancers, opening up new avenues of research that could be testable in other types of tumors,"* explains **Dr. Olivier Saulnier, Group Leader of the Genomics and Childhood Cancer Development team.**

### **Towards new therapeutic weapons against group 3 medulloblastoma**

By targeting exclusively the cell of origin, which is now identified, it is now possible to stop tumor development while sparing non-aggressive cells. Several innovative therapeutic approaches are being evaluated. These results make it possible to design the development of new therapies such as **antibodies targeting specifically PTRG protein**, which is expressed only on the surface of the "daughter" cells descending from the cell at the apex of medulloblastoma hierarchy. Another option could be **the use of cell therapy (CAR-T)**. Thus, by modifying the receptors on the surface of certain white blood cells, the T lymphocytes of an individual's immune system, they are specifically trained to fight the cells expressing PRTG protein and then re injected into the same individual and thus killing the tumor cells.

*"In addition to targeted therapies or innovative cell therapies, we are investigating other avenues in order to develop more effective and less invasive treatments for young patients. We are working on understanding the mechanisms ensuring the maintenance of this cell population during post-natal life, thus preventing the development of full-blown medulloblastoma tumors,"* concludes Dr. Olivier Saulnier.

#### **References:**

> **Early Rhombic Lip Protogenin+ve Stem Cells in a Human Specific Neurovascular Niche Initiate and Maintain Group 3 Medulloblastoma.** Abhirami Visvanathan\*, Olivier Saulnier\*, Chuan Chen\* (...) Dimiter S Dimitrov, Michael D. Taylor. *Cell*, July 5, 2024. DOI: <https://doi.org/10.1016/j.cell.2024.06.011>

<sup>1</sup> This work was carried out thanks to the collaboration of Institut Curie, The Hospital for Sick Children (Toronto, Canada), Baylor College of Medicine (Houston, USA), the University of Pittsburg (USA)

\*: first co-authors

*The work carried out by the team of Dr. Olivier Saulnier, Junior Principal Investigator at Institut Curie, was made possible thanks to the financial support and generosity of the public.*

#### **Press contacts:**

Elsa Champion - [elsa.champion@curie.fr](mailto:elsa.champion@curie.fr) / 07 64 43 09 28

Juliette Mamelonet – [juliette.mamelonet@havas.com](mailto:juliette.mamelonet@havas.com) / 01 58 47 90 12

#### **About Institut Curie**

Institut Curie, the first French center for the fight against cancer, combines an internationally renowned research center and a state-of-the-art hospital group that takes care of all cancers, including the rarest kinds. Founded in 1909 by Marie Curie, Institut Curie brings together on its three sites (Paris, Saint-Cloud, and Orsay) over 3,700 researchers, doctors, and caregivers who are all dedicated to work towards completing its three missions - care, research, and teaching. Recognized foundation of public utility authorized to receive donations and bequests, Institut Curie can, thanks to the support of its donors, accelerate discoveries and thus improve the treatments and the quality of life of the sick patients.

Find out more at: [curie.fr](http://curie.fr), [Twitter](#), [Facebook](#), [LinkedIn](#), [Instagram](#)